Menu
Annual · values2023202220212020
Operating Cash Flow-1.34 M USD-4235 USD-3308 USD
Depreciation & Amortization
Stock-Based Compensation
Capital Expenditures
Cash Flow from Investing
Cash Flow from Financing
Dividends Paid
Stock Buybacks-36.00 M USD0 USD
Free Cash Flow-818766 USD-4235 USD-461 USD

Bellevue Life Sciences Acquisition Corp. is a special purpose acquisition company (SPAC) focused on identifying and merging with a business in the life sciences sector. Designed to facilitate companies seeking public investment without undergoing a traditional Initial Public Offering (IPO), it raises capital through its own initial listing to fund potential acquisition targets. Bellevue Life Sciences Acquisition Corp. primarily targets industries such as biotechnology, pharmaceuticals, medical devices, and diagnostic services, which are pivotal for advancing healthcare solutions and technological innovations in medicine. The company leverages its leadership's expertise in navigating complex public markets and facilitating strategic growth for its chosen partner. As a SPAC, its significance in the financial market lies in its ability to provide a streamlined path for life sciences companies to access public capital, thereby accelerating research, development, and commercialization efforts in critical health-related fields. Through its structured approach, Bellevue Life Sciences Acquisition Corp. plays a vital role in expanding investment opportunities and fostering advancement in the high-demand area of life sciences.